Takafumi Yanagisawa retweeted
An inspiring evening with @BenjaminPradere: great lectures on #BladderCancer and conducting clinical trials, followed by dinner!
Takafumi Yanagisawa retweeted
Top10%閲覧論文に選ばれたようです。
Full text views:3744
Citations: 14...2025年に出版され、8ヶ月 (0.666年)で14 citesなので、この論文の瞬間最大IFは21点!(笑)
Comparison of ABI, ENZ, APA for mHSPC: A multicenter study - Yanagisawa T- 2025 - The Prostate onlinelibrary.wiley.com/doi/…
Takafumi Yanagisawa retweeted
🎉Our JHA group study on abiraterone, enzalutamide & apalutamide in mHSPC: Top 10 most-cited in The Prostate 2024!
onlinelibrary.wiley.com/doi/…
Takafumi Yanagisawa retweeted
📈Our systematic review and meta-analysis on prognostic factors of PSMA-targeted radioligand therapy in mCRPC is now featured on @UroToday's "Beyond the Abstract".
We discussed the key predictors for treatment outcomes. Check it out here:
urotoday.com/recent-abstract…
#mCRPC #PSMA
Takafumi Yanagisawa retweeted
🎆London calling : 13 abstracts from the Team Jikei Urology have been accepted by the EAU 🇬🇧🇬🇧🇬🇧
See you in London!
@gehi87
@F_Urabe
@Macchan1055
@ene1the1r0nk1d
Takafumi Yanagisawa retweeted
34th Malaysian Urological Conference:
MUC2025
Dr. Yanagisawa was invited and spoke at the Plenary session about En-bloc TUR-BT
and Dr. Enei gave a presentation about PSMA-RLT for the best poster competition
@gehi87
@Enenny_SS
@MyUrologyAssoc
Takafumi Yanagisawa retweeted
PSMAddition キタ〜
第III相PSMAddition試験は、mHSPC治療に放射性リガンド療法を導入
1,144例のPSMA陽性患者
ADT+ARPIに¹⁷⁷Lu-PSMA-617を追加投与することで、無再発生存期間(rPFS)が有意に改善(HR 0.72、p = 0.002)
85%がLu-PSMA全6サイクルを完了
Replying to @OncBrothers
1. #PSMAddition: PhIII, LuPSMA + ADT + ARPi vs. ADT + ARPi in mHSPC
- rPFS ⬆️ with LuPSMA (HR: 0.72)
- Higher xerostomia & neutropenia
- How many of these pts would’ve received Chemo + ADT +ARPi today outside trial?
- This will likely be another triplet available soon
3/11
Takafumi Yanagisawa retweeted
大変重要な議論でした
全員に6回必要?
PSMA陽性部位が少ないと効果落ちてAE増える
途中でPSMA陽性部位を確認する必要性を示唆
🎯Patient individualisation is a Must! For Patient selection and follow up! The aim is that the Patient live longer BUT also BETTER 🥇 #qualityoflife #PSMAddition #ESMO25 #prostatacancer @DrScottTagawa
Takafumi Yanagisawa retweeted
JSES IllustCon 17
📌Robot-Assisted Radical Nephrectomy and IVC Thrombectomy
📝The distal IVC was stapled and transected. IVC was cranially clamped and the Pringle maneuver was also performed. Then the tumor was directly identified and resected with IVC. These procedures are illustrated in a single figure.
🖊Dr.Cazz
#JSESイラストコンテスト #JSES_illustration_contest
Takafumi Yanagisawa retweeted
慈恵の柳澤先生らによる、mUCのメタ解析
EVPが効果1ランク上の模様だかAEも2位とのこと
link.springer.com/article/10…
Takafumi Yanagisawa retweeted
これが噂の、泌尿器科ドラマ!
39才女性の筋層浸潤膀胱癌はレアすぎて…?80歳のMIBCや結石性腎盂腎炎ならザラですが…
女医相手に下ネタが止まらない精巣腫瘍の患者もまあ不在です
ドラマ『まどか26歳、研修医やってます!』第4話「3科目は泌尿器科」
今回のローテンション先は「泌尿器科」自分は受診したことはないけど、この歳になっても泌尿器科って、けっこう抵抗あるな😅バリキャリの女性・成田友梨、膀胱癌のステージ2。気丈に振る舞ってるが…
#まどか26歳研修医やってます
Takafumi Yanagisawa retweeted
Radical cystectomy (RC) and trimodality therapy (TMT) yield comparable outcomes in muscle-invasive bladder cancer (MIBC)?
✨ 74.4% complete response with TMT.
🔄 23.1% recurrence rate in TMT-treated patients.
⚠️ 11.4% grade ≥3 toxicity for TMT.
Does this change your practice?
Takafumi Yanagisawa retweeted
Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis by Akihiro Matsukawa et al
buff.ly/3TRNPXK
#UroSoMe #MedTwitter #EUO #PCa #ProstateCancer
Takafumi Yanagisawa retweeted
Replying to @gehi87
@gehi87 from @jikei_urology talking about SR, MA & NMA! Dr Takafumi Yanagisawa is such a hardworking and talented researcher. Thank you for sharing with us your valuable experiences! #UroSoMe
Takafumi Yanagisawa retweeted
Replying to @Ric_Campi
@Ric_Campi discussing how @eau_yuo brings together today/tomorrows leaders to create teams for academic impact @Uroweb #ARISTA symposium @jteoh_hk @MRoupret @DocGauhar #Inspiring
Takafumi Yanagisawa retweeted
Recent advances in managing biochemical recurrence (BCR) after local treatment for prostate cancer (PCa) 🎯
📊 We analyzed 19 studies (9117 patients) to compare different salvage therapies post-radical prostatectomy (RP) or radiation therapy (RT). Results show that combining RT with hormone therapy offers significant improvements in metastatic-free survival (MFS)! 🌟
🔍 Key findings:
- RT + hormone therapy = ⬆️ MFS
- Best RT-based strategy: Prostate bed RT + elective nodal RT + ADT
- Top hormone-based strategy: Enzalutamide + ADT for MFS & OS
🧬 For high-risk BCR or post-RT recurrence, consider adding ARSI (androgen receptor signaling inhibitors) to ADT.
🚑 These combinations represent the next step in PCa care, ensuring better outcomes for patients!
pubmed.ncbi.nlm.nih.gov/3926…
#ProstateCancer #CancerResearch #urooncology #BCR #AndrogenTherapy #RadicalProstatectomy #RadiationTherapy #CancerTreatment
@ZilliThomas @joniau
Takafumi Yanagisawa retweeted
1st Int'l Urologic Cancer Symposium: Renowned urologists from 3 countries gave informative talks. Great dinner followed, joined by Dr. Teoh & Dr. Leung.
Takafumi Yanagisawa retweeted
Join us for the 1st Int'l Urologic Cancer Symposium in Tokyo!
8/28, 18:30-20:30 Jikei Uni.
Featuring @dr_rajwa, @BenjaminPradere & @FQuhal. Open to all, including non-institution members!
Takafumi Yanagisawa retweeted
First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy
@gehi87 @E_Laukhtina @K_Tatsushi @DrShariat @schmidingerRCC
doi.org/10.1111/bju.16336















































